文献速递急性肾损伤水电解质与酸碱

去甲肾上腺素治疗1型肝肾综合征时加用袢利尿剂

Addition of a Loop Diuretic to Norepinephrine During Treatment of Hepatorenal Syndrome Type 1.
PubMed 文献 · Kidney Int Rep · 2024-11-19

去甲肾上腺素引起的平均动脉压升高幅度与加用呋塞米后的尿量相关(r = 0.67,P = 0.0002)。结论提示在去甲肾上腺素充分治疗且平均动脉压有效提升的HRS-1患者中,加用静脉呋塞米可增强利尿而不影响肾功能恢复。

要点

  • 在去甲肾上腺素充分升压的HRS-1患者中,加用静脉呋塞米可显著增加尿量。
  • 加用呋塞米未对肾功能恢复产生负面影响,73%患者血肌酐轨迹维持或改善。
  • 去甲肾上腺素诱导的平均动脉压升高幅度与加用呋塞米后的尿量正相关。

核心结论

  • 在去甲肾上腺素充分治疗且平均动脉压有效提升的HRS-1患者中,加用静脉呋塞米可增强利尿而不 negatively 影响肾功能恢复。

研究设计与样本

  • 另设对照组22例未接受呋塞米。

主要发现

  • 加用呋塞米后尿量中位数从850 ml/d增至2072 ml/d(P < 0.0001),对照组无此变化。
  • 去甲肾上腺素诱导的平均动脉压升高幅度与加用呋塞米后的尿量相关(r = 0.67,P = 0.0002)。

关键数值与推荐

  • 呋塞米中位使用2天,剂量为160 mg静脉推注,每6-24小时一次。
  • 患者中位年龄51岁,91%为白人,36%为女性,中位MELD评分32,初始血肌酐中位数4.0 mg/dl。

临床怎么用

  • 对于接受去甲肾上腺素治疗且平均动脉压有效提升的HRS-1患者,可考虑加用静脉呋塞米以增强利尿,但需监测肾功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Diuretics are commonly discontinued in patients with cirrhosis with acute kidney injury (AKI) because they are presumed to trigger hepatorenal syndrome type 1 (HRS-1). We hypothesized that if HRS-1 is adequately treated with a vasoconstrictor (mean arterial pressure [MAP] effectively increased), diuretics are safe and effective. METHODS: Records of hospitalized patients with cirrhosis who received i.v. furosemide while receiving i.v. norepinephrine as a vasoconstrictor to treat HRS-1 were examined. We assessed change in urine output (UOP), trajectory of serum creatinine (sCr), and impact of portopulmonary hypertension (PoPHTN) on the therapeutic response. RESULTS: Twenty-six patients with HRS-1 received i.v. furosemide (median: 2 days, 160 mg boluses every 6-24 hours) added to i.v. norepinephrine. Median age was 51 years; 91% were of White race, 36% were women, and median model for end-stage liver disease score was 32. The median initial sCr was 4.0 mg/dl. Before treatment, median UOP was 358 ml/d. Norepinephrine alone led to a median increase in UOP to 850 ml/d. Addition of furosemide to norepinephrine induced a subsequent increase in median UOP to 2072 ml/d (P < 0.0001), which was not observed in a control group (n = 22) who did not receive furosemide. Nineteen patients (73%) treated with norepinephrine plus furosemide (median MAP increase, 16 mm Hg) either maintained or improved their sCr trajectory. The magnitude of norepinephrine-induced increase in MAP correlated with the norepinephrine plus furosemide-induced UOP (r = 0.67, P = 0.0002), and the correlation coefficient was numerically stronger among those with PoPHTN. CONCLUSION: In patients with HRS-1 who are adequately treated with norepinephrine and achieved an optimal MAP increment, addition of i.v. furosemide enhances diuresis without negatively affecting renal recovery.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Velez JCQ, Wickman TJ, Tayebi K, et al. Addition of a Loop Diuretic to Norepinephrine During Treatment of Hepatorenal Syndrome Type 1. Kidney Int Rep. 2024. PMID: 39990915. doi:10.1016/j.ekir.2024.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。